Biopharma Execs Go Face-To-Face With Obama Over TPP
This article was originally published in PharmAsia News
Executive Summary
President Barack Obama heard firsthand from a half dozen or so biopharmaceutical executives during an Oct. 8 White House face-to-face meeting about the industry's disappointment in the administration for agreeing to a minimum of five years of exclusivity protection for innovator biologics against biosimilars in the final TPP trade deal, rather than the 12 years required in the US by law.